2025年
1. Yamaya A, Sonoda K, Kawakita T, Koshiishi Y, Shingai M, Matsumoto M, Seya T. ARNAX, but not conventional adjuvants, alum and squalene, induces antigen-specific CD8+ T cell proliferation in vaccination with influenza split vaccine. Int Immunopharmacol. 2025 (in press).
2.Kawakita T, Sekiya T, Kameda Y, Nomura N, Ohno M, Handabile C, Yamaya A, Fukuhara H, Anraku Y, Kita S, Toba S, Tsukamoto H, Sawa T, Oshiumi H, Itoh Y, Maenaka K, Sato A, Sawa H, Suzuki Y, Brown LE, Jackson DC, Kida H, Matsumoto M, Seya T, Shingai M. ARNAX is an ideal adjuvant for COVID-19 vaccine to enhance antigen-specific CD4+ and CD8+ T cell responses and neutralizing antibody induction. J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290-24.
3.Handabile C, Ohno M, Sekiya T, Nomura N, Kawakita T, Kawahara M, Endo M, Nishimura T, Okumura M, Toba S, Sasaki M, Orba Y, Chua BY, Rowntree LC, Nguyen THO, Shingai M, Sato A, Sawa H, Ogasawara K, Kedzierska K, Kida H. Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine. Sci Rep. 2024 Feb 20;14(1):4204. doi: 10.1038/s41598-024-54421-1.
4.Shingai M, Iida S, Kawai N, Kawahara M, Sekiya T, Ohno M, Nomura N, Handabile C, Kawakita T, Omori R, Yamagishi J, Sano K, Ainai A, Suzuki T, Ohnishi K, Ito K, Kida H. Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire. J Virol. 2024 Mar 19;98(3):e0199523. doi: 10.1128/jvi.01995-23.
5.Seya T, Shingai M, Kawakita T, Matsumoto M. Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination. Cells. 2023 May 29;12(11):1504. doi: 10.3390/cells12111504. PMID: 37296625; PMCID: PMC10252737.
6. Sato,Y., A.Yamaya、K.Sonoda A. Wakita, Y. Nagaki, K. Kemuriyama, R.Sasamori, S. Nozaki, S. Takashima, K.Terata, K.Imai, M. Matsumoto, T. Seya, and Y. Minamiya. 2025. PolyI:C signaling induces robust CXCL10 production and apoptosis in human esophageal squamous cell carcinoma cells. Human Cell. (submitted).
2024年
1. Miyazaki, A., S. Yoshida, Y. Takeda, U. Tomaru, M. Matsumoto, T. Seya. 2024. Th1 adjuvant ARNAX, in combination with radiation therapy, enhances tumor regression in mouse tumor-implant models. Immunol Lett. 271:106947. doi: 10.1016/j.imlet.2024.106947.
2023年
1. Seya T. 2023. Innate-Acquired Linkage in Immunotherapy. Cells. 12(3): 371. doi: 10.3390/cells12030371.
2. Seya T, Shingai M, Kawakita T, Matsumoto M. 2023. Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination. Cells. 12(11): 1504. doi: 10.3390/cells12111504.
2022年
1.Seya, T., and M. Matsumoto. 2020. Seya, T., and M. Matsumoto. 2022. Toward developing harmless vaccines: ARNAX for prophylactic adjuvant. Cells.https://doi.org/10.3390/cells11244006
2.Iwata-Yoshikawa, N., N. Nagata, H. Takaki, M. Matsumoto, T. Suzuki, H. Hasegawa, T. Seya. 2022. Prophylactic vaccine targeting Toll-like receptor 3 (TLR3) on dendritic cells ameliorates eosinophilic pneumonia in a mouse SARS-CoV infection model. ImmunoHorizons. 6: 275-282 https://doi.org/10.4049/immunohorizons.2200020
2021年
1. Leong, C. R., T. Seya, T. W. Yenn, and W. N. Tan. 2021. Hepatitis B virus genomic nucleic acid in the activation and maturation of bone marrow-derived dendritic cells. AsPac J. Mol. Biol. Biotechnol. 29(4): 109-119.